[1]刘文静,赵艳秋,胡秀峰,等.紫杉醇脂质体联合替吉奥治疗晚期胃癌的有效性及安全性评价*[J].郑州大学学报(医学版),2014,(06):783.
 LIU Wenjing,ZHAO Yanqiu,HU Xiufeng,et al.Effectiveness and safety evaluation of paclitaxel liposome combined with S1 in treatment of advanced gastric cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2014,(06):783.
点击复制

紫杉醇脂质体联合替吉奥治疗晚期胃癌的有效性及安全性评价*
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2014年06期
页码:
783
栏目:
论著
出版日期:
2014-11-20

文章信息/Info

Title:
Effectiveness and safety evaluation of paclitaxel liposome combined with S1 in treatment of advanced gastric cancer
作者:
刘文静赵艳秋胡秀峰吴红波陈利娟吴慧娟王居峰#
郑州大学附属肿瘤医院内科 郑州 450008
Author(s):
LIU Wenjing ZHAO Yanqiu HU Xiufeng WU Hongbo CHEN Lijuan WU Huijuan WANG Jufeng
Department of Internal Medicine,the Affiliated Cancer Hospital, Zhengzhou University, Zhengzhou 450008
关键词:
紫杉醇脂质体替吉奥胶囊晚期胃癌
Keywords:
paclitaxel liposomeGimeracil and Oteracil Porassium capsulegastric cancer
分类号:
R735.2
摘要:
目的:评估紫杉醇脂质体和替吉奥联合治疗晚期胃癌的有效性和安全性。方法:选取符合研究标准的晚期胃癌患者61例(研究组30例,对照组31例),分别给予紫杉醇脂质体联合替吉奥或多西他赛+顺铂+氟尿嘧啶化疗方案(DCF)4个周期进行治疗,观察2组患者的客观疗效、无进展生存期和毒副反应。结果:研究组与对照组治疗的反应率(36.67% vs 45.16%;χ2=0.455,P=0.500)、控制率(86.67% vs 87.10%;χ2<0.001,P>0.999)差异均无统计意义,但中位无进展生存时间(32周 vs 24周;χ2=4.701,P=0.030)、白细胞减少(80.00% vs 96.77%;χ2=4.223,P=0.040)和贫血(70.00% vs 93.55%;χ2=5.720,P=0.017)的发生率差异均有统计学意义。结论:紫杉醇脂质体联合替吉奥化疗方案与DCF化疗方案疗效相当,但毒副反应明显减少。
Abstract:
Aim: To evaluate the efficacy and safety of paclitaxel liposome combined Gimeracil and Oteracil Porassium capsules(S1) treating advanced gastric cancer. Methods: The patients with advanced gastric cancer were selected by the study criteria and randomly assigned docetaxel+cisplatin+fluorouracil (DCF) chemotherapy or paclitaxel liposome combined with S1 4 cycles of treatment. The curative effect with objective, progression free survival and toxicity were observed in these two groups. Results: The baseline data had no statistically significant difference. Compared with control group, the treatment response rate (36.67% vs 45.16%;χ2=0.455, P=0.500) and control rate (86.67% vs 87.10%;χ2<0.001,P>0.999) of treatment group had no statistically significant difference, but the median PFS (32 weeks vs 24 weeks;χ2=4.701, P=0.030), leukopenia (80.00% vs 96.77%;χ2=4.223,P=0.040), anemia (70.00% vs 93.55%;χ2=5.720,P=0.017) had statistical significance. Conclusion: Compared with DCF chemotherapy, paclitaxel liposome combined with S1 chemotherapy can obtain the same effect and less toxicity.

参考文献/References:

[1]Ueda Y,Yamagishi H,Ichikawa D,et al.Multicenter phase Ⅱ study of weekly paclitaxel plus S1 combination chemotherapy in patients with advanced gastric cancer[J].Gastric Cancer,2010,13(3):149 [2]Van Cutsem E,Moiseyenko VM,Tjulandin S,et al.Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as firstline therapy for advanced gastric cancer: a report of the V325 study group[J].J Clin Oncol,2006,24(31):4991 [3]Ohno T,Horiguchi N,Asukai K,et al.A case of gastric cancer with peritoneal dissemination who achieved long survival from control of ascites for over 2 years by successive treatments with S1 in combination with docetaxel as firstline followed by irinotecan in combination with cisplatin as secondline[J].Gan To Kagaku Ryoho,2012,39(7):1123 [4]陈浩,许浪.胃癌组织中1,25二羟维生素D3、TGFβ1和Smad2蛋白的表达[J].郑州大学学报:医学版,2013,48(3):370 [5]陈志云, 陈佳, 谭清和,等. 多西他赛联合奥沙利铂、氟尿嘧啶治疗晚期胃癌临床观察[J].山东医药,2009,49(32):45 [6]张艳丽,吴 军,李凤婷. 以多西他赛为基础的三药联合与两药联合一线治疗晚期胃癌的疗效对比研究[J]. 实用心脑肺血管病杂志, 2013,21(10):38 [7]白瑶,段京莉.紫杉醇脂质体治疗非小细胞肺癌患者疗效与安全性的meta分析[J].药物不良反应杂志,2011,13(4):205 [8]Yang J,Zhou Y,Min K,et al.S1based vs nonS1based chemotherapy in advanced gastric cancer:a metaanalysis[J].World J Gastroenterol,2014,20(33):11886 [9]彭方慧,王峰,何炜,等.替吉奥与5氟尿嘧啶联合奈达铂治疗晚期食管癌的疗效比较[J].郑州大学学报:医学版,2013,48(2):160 [10]王婷, 马云.紫杉醇联合替吉奥一线治疗晚期胃癌25例生存分析[J].中国药业,2013,22(5):69 [11]周恒根, 倪敬中, 刘兰芳,等. 替吉奥胶囊联合紫杉醇治疗晚期胃癌28例临床观[J].中国现代药物应用,2011,5(11):3

备注/Memo

备注/Memo:
*河南省卫生厅科技攻关项目2011020170;#通讯作者,男,1965年5月生,硕士,主任医师,研究方向:消化道肿瘤,Email:13783583966@163.com
更新日期/Last Update: 2014-11-26